Clinical trial design and development work group within the quantitative imaging network

Ella F. Jones; John M. Buatti; Hui Kuo Shu; Richard L. Wahl; Brenda F. Kurland; Hannah M. Linden; David A. Mankoff; Daniel L. Rubin; Darrell Tata; Robert J. Nordstrom; Lubomir Hadjiyski; Matthias Holdhoff; Lawrence H. Schwartz

doi:10.18383/j.tom.2019.00022

Clinical trial design and development work group within the quantitative imaging network

Ella F. Jones, John M. Buatti, Hui Kuo Shu, Richard L. Wahl, Brenda F. Kurland, Hannah M. Linden, David A. Mankoff, Daniel L. Rubin, Darrell Tata, Robert J. Nordstrom, Lubomir Hadjiyski, Matthias Holdhoff, Lawrence H. Schwartz

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.

Original language	English (US)
Pages (from-to)	60-64
Number of pages	5
Journal	Tomography
Volume	6
Issue number	2
DOIs	https://doi.org/10.18383/j.tom.2019.00022
State	Published - Jun 2020

Keywords

Clinical Trial Design and Development (CTDD)
Quantitative Imaging Network (QIN)

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.18383/j.tom.2019.00022

Cite this

@article{a4b302a407e24f1290a68db813deb32a,

title = "Clinical trial design and development work group within the quantitative imaging network",

abstract = "The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.",

keywords = "Clinical Trial Design and Development (CTDD), Quantitative Imaging Network (QIN)",

author = "Jones, {Ella F.} and Buatti, {John M.} and Shu, {Hui Kuo} and Wahl, {Richard L.} and Kurland, {Brenda F.} and Linden, {Hannah M.} and Mankoff, {David A.} and Rubin, {Daniel L.} and Darrell Tata and Nordstrom, {Robert J.} and Lubomir Hadjiyski and Matthias Holdhoff and Schwartz, {Lawrence H.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors.",

year = "2020",

month = jun,

doi = "10.18383/j.tom.2019.00022",

language = "English (US)",

volume = "6",

pages = "60--64",

journal = "Tomography",

issn = "2379-1381",

publisher = "Grapho Publications LLC",

number = "2",

}

TY - JOUR

T1 - Clinical trial design and development work group within the quantitative imaging network

AU - Jones, Ella F.

AU - Buatti, John M.

AU - Shu, Hui Kuo

AU - Wahl, Richard L.

AU - Kurland, Brenda F.

AU - Linden, Hannah M.

AU - Mankoff, David A.

AU - Rubin, Daniel L.

AU - Tata, Darrell

AU - Nordstrom, Robert J.

AU - Hadjiyski, Lubomir

AU - Holdhoff, Matthias

AU - Schwartz, Lawrence H.

PY - 2020/6

Y1 - 2020/6

N2 - The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.

AB - The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.

KW - Clinical Trial Design and Development (CTDD)

KW - Quantitative Imaging Network (QIN)

UR - http://www.scopus.com/inward/record.url?scp=85086685407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086685407&partnerID=8YFLogxK

U2 - 10.18383/j.tom.2019.00022

DO - 10.18383/j.tom.2019.00022

M3 - Article

C2 - 32548281

AN - SCOPUS:85086685407

SN - 2379-1381

VL - 6

SP - 60

EP - 64

JO - Tomography

JF - Tomography

IS - 2

ER -

Clinical trial design and development work group within the quantitative imaging network

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this